Tricida, Inc. (TCDA)
Tricida, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in South San Francisco, CA, US. The stock last traded at $0.11, up 0.00% on the session, giving a market capitalisation of $6.0M. On trailing twelve-month figures it carries a trailing P/E of -0.03, a net margin of 0.0%. Its beta of 0.00 implies it has historically moved less than the broad market.
Tricida, Inc. operates as a biopharmaceutical firm with a primary focus on the advancement and market introduction of veverimer (TRC101). This compound, an orally ingested, non-systemic polymer, has successfully concluded its Phase III clinical trials. Veverimer is designed to address metabolic acidosis in individuals suffering from chronic kidney disease by specifically targeting and eliminating excess acid within the gastrointestinal tract. The company was established in 2013 and is headquartered in South San Francisco, California.
Tricida, Inc. is most often compared with the following Healthcare names: